"Engaging [AngelMD's] network of physicians has been invaluable in providing feedback for our product pipeline and clinical direction,” said Greg King, CEO of Fibralign Corp.
Seattle, WA (PRWEB) November 27, 2017
AngelMD,an investment and networking platform connecting innovative medical startups, physicians, investors, and industry partners, today announced that it has completed a Syndicate funding round for Fibralign, Inc. Fibralign produces therapeutic medical devices that target unmet needs in regenerative medicine using the company's patented Nanoweave® 3D scaffolding technology.
The company's first product, BioBridge®, directly addresses an area of concern for cancer and cosmetic surgery patients who suffer from secondary lymphedema. The World Health Organization estimates that over 15 million people suffer from cancer-related lymphedema -- a disease which has no cure and causes long-term physical, psychological, and social problems for patients. BioBridge is a thread-like device that reinforces weak areas of soft tissue such as those repaired by sutures.
"Secondary lymphedema, which occurs when the lymphatic system is disrupted and unable to transport interstitial fluid, most commonly occurs as a result of cancer treatments in western countries," said Syndicate Leader Dr. Orrin Ailloni-Charas, an Anesthesiologist in the Bay Area of California. "Conventional therapies are costly, marginally successful, and treat symptoms only. To an area in great need of a new approach, the team at Fibralign has introduced a novel BioBridge Collagen Matrix which acts as a 3D scaffolding to promote the growth of new lymphatic vessels and dramatically improve the quality of life for millions of people."
Beyond the company's initial market, BioBridge also has significant follow-on opportunities for treating ischemia, cell/drug delivery, and gene therapy (mmRNA).
"We are honored to have AngelMD join us and support our advancement of a much-needed treatment for lymphedema” said Greg King, CEO of Fibralign Corp. “AngelMD brings much more than capital with its investment to Fibralign. Engaging their network of physicians has been invaluable in providing feedback for our product pipeline and clinical direction.”
Fibralign has assembled a strong, multi-discipline, cross-functional team that consist of eight full-time and seven part-time members whose deep experience span across biotech, engineering, materials science, operations, process development and market/business development. Team members have worked in relevant biotech GLP/GMP commercial enterprises, spanning process development (Collagen Corp.), biomedical engineering, product development and QA/QC (J&J DePuy Synthes).
AngelMD is an investment and networking platform connecting innovative medical startups, physicians, investors, and industry partners. Leading physicians from all over the US have joined AngelMD to help source, evaluate and advise companies in biotechnology, medical device, and healthcare technology. For more information, visit http://www.angelmd.co.
Fibralign Corporation produces advanced therapeutic medical devices that utilize its patented Nanoweave® 3D scaffolding technology to meet major unmet medical needs. http://www.fibralignbio.com